IP Library › Granted Patent US 12,358,974
Granted Patent B2
US 12,358,974 · App. 18/774,608 · Granted Jul 15, 2025

Compositions and methods for treating synucleinopathies

Inventors: Josefine Nielsen Søderberg (Valby, DK); Pekka Kallunki (Valby, DK); Louise Buur (Valby, DK); Frank Larsen (Valby, DK)
Assignee: H. Lundbeck A/S
C07K16/18A61K39/39591A61K47/22A61K47/26A61K2039/545C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,974
App. No.
18/774,608
Granted
Jul 15, 2025
Kind
B2
Abstract

The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and/or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.

Claims (33)

1. A method of treating multiple system atrophy (MSA) in a human patient, the method comprising intravenously administering an anti-alpha synuclein antibody at a dose of 4200 mg once every 4 weeks to the patient, wherein the antibody is a human IgG1, kappa monoclonal antibody which comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 34, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively.

2. The method of claim 1 , wherein the antibody comprises a heavy chain variable domain and a light chain variable domain comprising the amino acid sequences of SEQ ID NOs: 31 and 8, respectively.

3. The method of claim 1 , wherein the antibody comprises a constant heavy chain domain comprising the amino acid sequence of SEQ ID NO: 18 and a kappa light chain constant domain comprising the amino acid sequence of SEQ ID NO: 17.

4. The method of claim 1 , wherein the binding affinity of the antibody for the oligomeric form of alpha synuclein displays approximately a 65- to 75-fold enhancement relative to the binding affinity of the antibody for the monomeric form of alpha synuclein.

5. The method of claim 1 , wherein the antibody has a half-life in the human patient of about 28-30 days.

6. The method of claim 1 , wherein the MSA is possible MSA, probable MSA, MSA type C, MSA type P, clinically established MSA, or clinically probable MSA.

7. The method of claim 1 , wherein the treatment of MSA delays disease progression.

8. The method of claim 1 , wherein the treatment of MSA delays clinical progression.

9. The method of claim 1 , wherein the antibody is administered at least 3 times at about 4 week intervals to achieve a CSF mean steady state concentration of the antibody in the patient of at least 12 nM.

10. The method of claim 1 , wherein the antibody is administered at least 3 times at about 4 week intervals to achieve a target engagement of oligomeric forms of alpha synuclein in the CSF of the patient of at least 95%.

11. A method of treating multiple system atrophy (MSA) in a human patient, the method comprising intravenously administering an anti-alpha synuclein antibody at a dose of 4200 mg once monthly to the patient, wherein the antibody is a full length monoclonal antibody which comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 34, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively.

12. The method of claim 11 , wherein the antibody comprises a heavy chain variable domain and a light chain variable domain comprising the amino acid sequences of SEQ ID NOs: 31 and 8, respectively.

13. The method of claim 11 , wherein the antibody comprises a constant heavy chain domain comprising the amino acid sequence of SEQ ID NO: 18 and a kappa light chain constant domain comprising the amino acid sequence of SEQ ID NO: 17.

14. The method of claim 11 , wherein the antibody is a human IgG1 antibody.

15. The method of claim 11 , wherein the binding affinity of the antibody for the oligomeric form of alpha synuclein displays approximately a 65- to 75-fold enhancement relative to the binding affinity of the antibody for the monomeric form of alpha synuclein.

16. The method of claim 11 , wherein the antibody has a half-life in the human patient of about 28-30 days.

17. The method of claim 11 , wherein the MSA is possible MSA, probable MSA, MSA type C, MSA type P, clinically established MSA, or clinically probable MSA.

18. The method of claim 11 , wherein the treatment of MSA delays disease progression.

19. The method of claim 11 , wherein the treatment of MSA delays clinical progression.

20. The method of claim 11 , wherein the antibody is administered at least 3 times at about monthly intervals to achieve a CSF mean steady state concentration of the antibody in the patient of at least 12 nM.

21. The method of claim 11 , wherein the antibody is administered at least 3 times at about monthly intervals to achieve a target engagement of oligomeric forms of alpha synuclein in the CSF of the patient of at least 95%.

22. A method of treating multiple system atrophy (MSA) in a human patient, the method comprising intravenously administering an anti-alpha synuclein antibody at a dose of 4200 mg once every 4 weeks to the patient, wherein the antibody is a human IgG1 antibody which comprises a heavy chain variable domain and a light chain variable domain comprising the amino acid sequences of SEQ ID NOs: 31 and 8, respectively.

23. The method of claim 22 , wherein the antibody comprises a constant heavy chain domain comprising the amino acid sequence of SEQ ID NO: 18 and a kappa light chain constant domain comprising the amino acid sequence of SEQ ID NO: 17.

24. A method of treating multiple system atrophy (MSA) in a human patient, the method comprising intravenously administering an anti-alpha synuclein antibody at a dose of 4200 mg once monthly to the patient, wherein the antibody is a human IgG1 antibody which comprises a heavy chain variable domain and a light chain variable domain comprising the amino acid sequences of SEQ ID NOs: 31 and 8, respectively.

25. The method of claim 24 , wherein the antibody comprises a constant heavy chain domain comprising the amino acid sequence of SEQ ID NO: 18 and a kappa light chain constant domain comprising the amino acid sequence of SEQ ID NO: 17.

26. The method of claim 1 , wherein the treatment of MSA slows clinical progression.

27. The method of claim 26 , wherein the slowing of clinical progression is quantified by Unified Multiple System Atrophy Rating Scale UMSARS score.

28. The method of claim 26 , wherein the slowing of clinical progression is quantified by Unified Multiple System Atrophy Rating Scale modified UMSARS score.

29. The method of claim 26 , wherein the slowing of clinical progression is quantified by UMSARS total score.

30. The method of claim 11 , wherein the treatment of MSA slows clinical progression.

31. The method of claim 30 , wherein the slowing of clinical progression is quantified by UMSARS score.

32. The method of claim 30 , wherein the slowing of clinical progression is quantified by modified UMSARS score.

33. The method of claim 30 , wherein the slowing of clinical progression is quantified by UMSARS total score.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2024
From: NIELSEN SØDERBERG, JOSEFINE; KALLUNKI, PEKKA; BURR, LOUISE; LARSEN, FRANK; PARSHAD, HENRIK RAJESH KUMAR; MARKUSSEN, ANNE SOFIE
To: H. LUNDBECK A/S
Reel/Frame 068020/0627 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2024
From: MANNING, MARK CORNELL; KATAYAMA, DERRICK SPENCER
To: LEGACY BIODESIGN LLC
Reel/Frame 068020/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2024
From: LEGACY BIODESIGN LLC
To: H. LUNDBECK A/S
Reel/Frame 068020/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2024
From: GAUDEN, MAGDALENA; SMITH, JOHN
To: LONZA BIOLOGICS PLC
Reel/Frame 068020/0767 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2024
From: LONZA BIOLOGICS PLC
To: H. LUNDBECK A/S
Reel/Frame 068020/0832 →
Priority Claims (1)
EP 21197120 · Sep 16, 2021 · regional
Continuity (3)
Division 18341437 · Jun 26, 2023
Continuation PCTEP2022075402 · Sep 13, 2022
Related Publication 20240400660A1 · Dec 5, 2024
References Cited (58)
US 10358482B2 · Kallunki et al. · 2019 [cited by applicant]
US 10358483B2 · Kallunki et al. · 2019 [cited by applicant]
US 10358484B2 · Kallunki et al. · 2019 [cited by applicant]
US 10364285B2 · Kallunki et al. · 2019 [cited by applicant]
US 10640554B2 · Kallunki et al. · 2020 [cited by applicant]
US 10647763B2 · Kallunki et al. · 2020 [cited by applicant]
US 10647764B2 · Kallunki et al. · 2020 [cited by applicant]
US 10800836B2 · Kallunki et al. · 2020 [cited by applicant]
US 11421024B2 · Kallunki et al. · 2022 [cited by applicant]
US 11524995B2 · Kallunki et al. · 2022 [cited by applicant]
US 11542323B2 · Kallunki et al. · 2023 [cited by applicant]
US 12077578B2 · Nielsen SøDerberg et al. · 2024 [cited by examiner]
US 20170015739A1 · Kallunki et al. · 2017 [cited by applicant]
US 20180127491A1 · Kallunki et al. · 2018 [cited by applicant]
US 20180127492A1 · Kallunki et al. · 2018 [cited by applicant]
US 20180179270A1 · Kallunki et al. · 2018 [cited by applicant]
US 20190367594A1 · Kallunki et al. · 2019 [cited by applicant]
US 20190367595A1 · Kallunki et al. · 2019 [cited by applicant]
US 20190382473A1 · Kallunki et al. · 2019 [cited by applicant]
US 20210061892A1 · Kallunki et al. · 2021 [cited by applicant]
US 20210147522A1 · Kallunki et al. · 2021 [cited by applicant]
US 20230312693A1 · Kallunki et al. · 2023 [cited by applicant]
US 20240025979A1 · Nielsen Soderberg · 2024 [cited by applicant]
US 20240400661A1 · Nielsen Søderberg et al. · 2024 [cited by applicant]
US 20240400662A1 · Nielsen Søderberg et al. · 2024 [cited by applicant]
WO 2005013889A2 · 2005 [cited by applicant]
WO 2015001504A2 · 2015 [cited by applicant]
WO 2017009312A1 · 2017 [cited by applicant]
WO 2017176835A2 · 2017 [cited by applicant]
WO 2018091444A1 · 2018 [cited by applicant]
WO 2018178950A1 · 2018 [cited by applicant]
A Study of Lu AF82422 in Participants With Multiple System Atrophy—Full Text View—ClinicalTrials.gov, 7 pages (NCT05104476), Nov. 3, 2021, 7 pages. [cited by applicant]
Jankovic, J. et al., “Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease,” JAMA Neurol., vol. 75(10):1206-1214 (2018). [cited by applicant]
Luk, K. et al.“Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice,” J. Exp. Med., vol. 209(5):975-986 (2012). [cited by applicant]
Luk, K. et al., “Pathological a-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Non-transgenic Mice,” Science, vol. 338(6109): 949-953 (2012). [cited by applicant]
Mollenhauer, B. et al., “Longitudinal Analyses of Cerebrospinal Fluid ?-Synuclein in Prodromal and Early Parkinson's Disease,” Mov Disord., vol. 34(9): 1354-1364 (2019). [cited by applicant]
Peelaerts, W. et al., “alpha-synuclein strains cause district synucleinopathies after local and systemic administration,” Nature, vol. 522 (7556) 340-344 (2015). [cited by applicant]
Polinski, N. et al., “Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents,” J. Parkinsons Dis., vol. 8(2): 303-322 (2018). [cited by applicant]
Recasens, A. PhD, et al. “Lewy body extracts from Parkinson disease brains trigger alphasynuclein pathology,” Ann Neurol., vol. 75:351-362 (2014). [cited by applicant]
Tateno, F. et al., “Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease,” Alzheimer Dis Assoc Disord… [cited by applicant]
Volpicelli-Daley, L. et al., “Exogenous a-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death,” Neuron, vol. 72, 57-71 (2011). [cited by applicant]
Wenning, G. et al., “The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy,” The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders, vol. 37… [cited by applicant]
U.S. Appl. No. 18/774,646, filed Jul. 16, 2024, Henrik Rajesh Kumar Parshad. [cited by applicant]
U.S. Appl. No. 18/774,629, filed Jul. 16, 2024, Josefine Nielsen Soderberg. [cited by applicant]
U.S. Appl. No. 18/773,301, filed Jul. 16, 2024, Josefine Nielsen Soderberg. [cited by applicant]
U.S. Appl. No. 18/341,437, filed Jun. 26, 2023, Josefine Nielsen Soderberg, US 20240025979. [cited by applicant]
U.S. Appl. No. 17/992,403, filed Nov. 22, 2022, Pekka Kallunki, US 20230312693. [cited by applicant]
U.S. Appl. No. 17/088,307, filed Nov. 3, 2020, Pekka Kallunki, U.S. Pat. No. 11,542,323. [cited by applicant]
U.S. Appl. No. 17/004,447, filed Aug. 3, 2022, Pekka Kallunki, U.S. Pat. No. 11,421,024. [cited by applicant]
U.S. Appl. No. 16/895,471, filed Jun. 8, 2020, Pekka Kallunki, U.S. Pat. No. 11,524,995. [cited by applicant]
U.S. Appl. No. 16/443,249, filed Jun. 17, 2019, Pekka Kallunki, U.S. Pat. No. 10,640,554. [cited by applicant]
U.S. Appl. No. 16/443,225, filed Jun. 17, 2019, Pekka Kallunki U.S. Pat. No. 10,647,764. [cited by applicant]
U.S. Appl. No. 16/443,187, filed Jun. 17, 2019, Pekka Kallunki, U.S. Pat. No. 10,647,763. [cited by applicant]
U.S. Appl. No. 15/812,410, filed Nov. 14, 2017, Pekka Kallunki, U.S. Pat. No. 10,358,484. [cited by applicant]
U.S. Appl. No. 15/812,363, filed Nov. 14, 2017, Pekka Kallunki, U.S. Pat. No. 10,364,285. [cited by applicant]
U.S. Appl. No. 15/812,303, filed Nov. 14, 2017, Pekka Kallunki, U.S. Pat. No. 10,358,483. [cited by applicant]
U.S. Appl. No. 15/812,251, filed Nov. 14, 2017, Pekka Kallunki, U.S. Pat. No. 10,358,482. [cited by applicant]
U.S. Appl. No. 15/207,859, filed Jul. 12, 2016, Pekka Kallunki, U.S. Pat. No. 10,800,836. [cited by applicant]